IHL’s Application Process On Track To Obtain License To Import, Store, Distribute And Export Of Medicinal Cannabis Products

Impression Healthcare Limited (ASX: IHL), the mouthguard maker has become serious about becoming a pot stock. For that reason, it has started the lengthy process of applying for local cannabis licenses.

After the news regarding the Marijuana stock performance of 127 percent to 3.4c, it has attracted many starved investors. Impression has applied for the license in order to import, store, distribute and export medicinal Cannabis products. The license is applied to Victoria Department of Health and the Office of Drug Control (ODC). At present it is reported that ODC is working with eight month old backlog applications. Impression who is considered best for anti-snoring mouth guards, has entered into an agreement with the US cannabis researcher AXIM Biotechnologies to act as a local distributor for them.   [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]

AXIM is a $US114 million company that trades over-the-counter in the US. The company develops a wide variety of cannabis-based products which also includes its flagship chewing gums MedChew Rx that is designed to treat patients having symptoms of Multiple Sclerosis and CanChew RL which is used to treat restless leg syndrome.

Impression is planning to sell AXIM’s medical products in Australia under the Special Access Schemes and through the Authorized Prescriber Network. They are hopeful by March 2019 they would be getting licenses and extra security at their Melbourne factory.

For the year ended 2018, the company made a net loss of $2,947,991 million. The total assets of the company was $707,857 and total liabilities of $1,091,175. As a result, the company has net liabilities worth $383,318. The company is not in a position to clear long term obligations. The total current asset of the company is $539,113 and total current liabilities $1,091,175. This shows that company is not is a position to clear even short term obligations. There is net deficiency in the shareholders equity. The net cash used in the operating activities was $2,851,020 where the major cash outflow was due to the payment made to the suppliers and the employees worth $4,143,833. The company made payment for plant, property and equipment worth $47,600 as a result, the net cash used in the investing activities worth $47,600. The company has made a debt repayment of $200,000. It generated an amount of $2,820,115 from the share which they issued after netting of the cost. The net cash from the financing activities is $2,620,115. The company reported a net decrease in the cash and cash equivalent of $278,505. The net cash and cash equivalent at the end of the year was $228,406.

The market price of the share traded at A$0.022 with market capitalization of A$5.16 million as at October 24, 2018.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report